研究报告 Research Report

31 Aug 2025

# 信达生物 Innovent Biologics (1801 HK)

## 稳步推进五年战略规划，国际化战略开始加速

The five-year strategic plan is being steadily advanced, while the internationalization strategy is beginning to accelerate

观点聚焦 Investment Focus

**维持优于大市 Maintain OUTPERFORM**

| | |
|---|---|
| 评级 | 优于大市 OUTPERFORM |
| 现价 | HK$96.85 |
| 目标价 | HK$105.80 |
| HTI ESG | 3.6-1.4-3.5 |

*E-S-G: 0-5, (Please refer to the Appendix for ESG comments)*

| | |
|---|---|
| 市值 | HK$165.88bn / US$21.28bn |
| 日交易额 (3 个月均值) | US$262.75mn |
| 发行股票数目 | 1,713mn |
| 自由流通股 (%) | 90% |
| 1 年股价最高最低值 | HK$101.90-HK$30.00 |

注：现价 HK$96.85 为 2025 年 08 月 29 日收盘价


*资料来源：Factset*

| | 1mth | 3mth | 12mth |
|---|---|---|---|
| 绝对值 | 3.1% | 60.9% | 119.6% |
| 绝对值（美元） | 3.9% | 61.8% | 119.7% |
| 相对 MSCI China | 1.6% | 50.6% | 74.2% |

| Rmb mn | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| Revenue | 9,422 | 12,581 | 15,186 | 18,691 |
| Revenue (+/-) | 52% | 34% | 21% | 23% |
| Net profit | -206 | 1,375 | 1,420 | 1,817 |
| Net profit (+/-) | n.m. | -767% | 3% | 28% |
| Diluted EPS (Rmb) | -0.13 | 0.84 | 0.87 | 1.12 |
| GPM | 84.0% | 83.7% | 84.7% | 88.0% |
| ROE | -1.6% | 9.5% | 8.9% | 10.3% |
| P/E | n.m. | 105 | 102 | 79 |

*资料来源：公司信息, HTI*

(Please see APPENDIX 1 for English summary)

### 事件

公司公布 25H1 业绩：收入 59.5 亿元（+50.6%），总产品收入超 52.3 亿元（+37.3%），25Q2 产品收入超 27 亿元（+30%，环比 +13%）。毛利 51.2 亿元（+56.3%），毛利率 86.0%（+3.1pcts），研发费用 10.0 亿元（-28.0%），研发费用率 16.9%（-18.5pcts），销售费用 23.8 亿元（+26.4%），占产品收入 45.4%（-3.9pcts）。期内利润 8.3 亿元（去年同期-3.9 亿元）。公司在手现金储备超 20 亿 USD。

### 点评

**稳步推进五年战略规划，国际化战略开始加速。**国内商业化表现稳步提升，产品持续增长主要得益于肿瘤板块的稳固基础，以及 CVM 板块的双轮驱动：1）肿瘤领域 PD-1 等产品品牌和产品组合优势明显，KRAS G12C、三代 EGFR-TKI 等新产品贡献营收；2）综合管线中 PCSK9、IGF-1R 等新产品准入顺利，快速放量。玛仕度肽也顺利获批。利润端实现 8.3 亿元利润超市场预期，主要由于确认了罗氏引进 DLL3 ADC 的 8000w USD 首付款以及研发费用效率优化。考虑到 IBI363（PD-1/IL-2$^{\alpha\text{-bias}}$）的全球 MRCT 临床开展、玛仕度肽、IBI112（IL-23p19）、IBI128（XOI）的 III 期临床开展以及早期管线入组节奏，我们认为公司下半年研发费用会高于上半年，全年维持在 21~28 亿元区间。

公司创始人俞德超博士再次强调，公司正按既定路径稳步推进：预计 2025 年实现 EBITDA 盈利，2027 年国内营收达到 200 亿元，2030 年至少 5 个管线进入全球多中心 III 期临床研究。明确的战略目标彰显了公司迈向全球一流生物医药企业的决心，也为市场信心提供了有力支撑。公司亦强调国际化布局，积极在全球范围引进临床开发、运营及供应链人才，为 IBI363 等产品的海外临床奠定坚实基础。


**孟科含 Kehan Meng**
kh.meng@htisec.com

**宁嘉骏 Jiajun Ning, PhD**
jj.ning@htisec.com

**肿瘤领域：IBI363 有望成为下一代 IO 基石药物，新一代 ADC 推动“IO+ADC”组合疗法升级。**

**IBI363 末线到前线/围手术期，IO 经治、“冷肿瘤”全面布局。**IO 初治黑色素瘤（粘膜/肢端）的关键性研究正在进行中；肺癌领域，针对 IO 耐药的 sqNSCLC，公司已启动全球多中心 III 期研究（MRCT），计划在中国、日本、美国、加拿大、欧盟及英国等地招募约 600 例患者，评估 IBI363（3 mg/kg 单药）相较多西他赛在经铂类化疗及抗 PD-1/PD-L1 治疗后进展的无法手术切除局部晚期 nqNSCLC 患者中的疗效与安全性，主要研究终点为 OS。同时，公司在 3L mss CRC 适应症上正筹备开展 III 期临床研究；在一线 NSCLC 及一线 CRC 方面，I/IIb 期研究已在计划中，预计将于 2026 年陆续读出数据。此外，公司还在积极拓展其他适应症，包括铂耐药卵巢癌、EGFR 突变 NSCLC 以及 nsqNSCLC 新辅助治疗等。

**双抗/双 payload ADC、三抗 TCE 蓄势待发。**IBI3001（EGFR/B7H3 ADC）正在中美澳全球爬坡中，确定剂量后会探索联合疗法。IBI3020（CEACAM5 dp ADC）采用自主研发毒素，克服耐药，同时优化 linker 保持稳定性，提高治疗窗口。目前全球 I 期剂量爬坡中，以及爬升到较高剂量，有望 25 年取得 POC 数据。公司也重点强调了 IBI3003（GPRC5D/BCMA/CD3）具备同类最佳潜力，目前中澳 I 期临床爬坡中，美国患者即将入组。公司在爬坡中看到不错结果，在 MM 适应症中 ORR、CR 率有望媲美 CAR-T 疗法，有望解决 GPRC5D、BCMA 单靶疗法出现耐药问题。

**CVM 领域：玛仕度肽有望成为国内减重降糖护肝领导品牌，叠加渠道布局加速放量。**

**玛仕度肽有望加速放量。**玛仕度肽的 T2D 适应症有望 25H2 获批，同时青少年肥胖适应症的 III 期临床即将启动。公司表示玛仕度肽的市场反馈不错。我们认为玛仕度肽定价较双靶竞品低约 30%，叠加线上线下渠道协同，有望实现快速放量。

**GLP-1 口服小分子有差异化优势：**公司表示 IBI3032 虽然采用 Orforglipron 骨架，但半衰期更长，口服暴露量是同类分子 5-10 倍，并且专利风险较小。其他适应症比如高血压也有潜力，和其他 CVM 管线（XOI 等）形成协同，有望成为下一代基石产品。

**公司 25 年研发催化剂丰富。推荐关注：**

1） IBI363：3L mssCRC 的 III 期临床研究开展；1L NSCLC、1L CRC 的 I/IIb 研究数据有望读出（26 年）。

2） IBI343（CLDN18.2 ADC）：2L 胰腺癌全球 MRCT 注册研究有望开展（25H2-26）；1L 胰腺癌的 I 期数据读出。

3） IBI354（HER2 ADC）：铂耐药卵巢癌的 III 期数据读出；HER2+ BC 的 III 期有望开展。

4） IBI3003（GPRC5D/BCMA/CD3）：I 期数据读出（25H2）。

5） 玛仕度肽：T2D 适应症获批（25H2）；Dreams-3 研究顶线数据读出（25H2）；GLORY-2 研究顶线数据读出（25H2）；青少年肥胖 I 期数据读出，III 期研究启动（25H2）。

6） IBI128（XOI）：II 期数据在亚太风湿病学会年会读出（25.09）以及 III 期研究启动（25H2）。

7） IBI3032（GLP-1 口服小分子）：25Q3 进入中美 I 期，部分数据有望读出（25H2）。

8） IBI3002（TSLP/IL-4Rα）：初步数据读出（25H2）。

9） IBI356（OX40L）：I 期数据潜在读出，以及 II 期启动（25H2）。

IBI3016（AGT siRNA）：I 期数据在美国 2025 AHA 大会读出（25H2）。

**盈利预测及估值建议：**

结合公司 2025 H1 年营收情况、我们上调了公司盈利预测以及更新估值模型。我们预计 2025-27 年总收入为 125.8/151.9/186.9 亿元（2025-27E 前值：118.6/143.4/181.7），同比+34/+21/+23%。2025 年扭亏为盈，实现净利润 13.8 亿元（前值 3.8 亿元）。我们采用 DCF 模型对公司进行估值，采用 FY26-37 现金流进行测算，基于 WACC 9.8%（不变），永续增长率 3.5%（不变），假设汇率 RMB:HKD=1:1.14，调整目标价至 105.8 HKD/股（前值：90.1 HKD/股），维持“优于大市”评级。

**风险提示：**新药研发风险，新药审批风险，新药商业化不及预期风险。

**表 1. DCF 估值模型**

| RMB m | FY24A | FY25E | FY26E | FY27E | FY28E | FY29E | FY30E | FY31E | FY32E | FY33E | FY34E | FY35E | FY36E | FY37E |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 |
| Forecast Year | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 8 |
| Time Factor | 0.0 | 0.3 | 1.3 | 2.3 | 3.3 | 4.3 | 5.3 | 6.3 | 7.3 | 8.3 | 9.3 | 10.3 | 11.3 | 12.3 |
| (fraction of year to next FY end) | | | | | | | | | | | | | | |
| **Sales** | **9422** | **12581** | **15186** | **18691** | **21488** | **24934** | **27961** | **30382** | **32604** | **34216** | **35599** | **36607** | **37568** | **38500** |
| *... Growth* | *51.8%* | *33.5%* | *20.7%* | *23.1%* | *15.0%* | *16.0%* | *12.1%* | *8.7%* | *7.3%* | *4.9%* | *4.0%* | *2.8%* | *2.6%* | *2.5%* |
| Gross Profit | 7912 | 10529 | 12861 | 16448 | 18909 | 21942 | 24605 | 26736 | 28691 | 30111 | 31327 | 32214 | 33060 | 33880 |
| *... GP Margin* | *84.0%* | *83.7%* | *84.7%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* | *88.0%* |
| SG&A | -8668 | -9477 | -11756 | -14876 | -16357 | -17127 | -18146 | -19203 | -20233 | -20858 | -21318 | -21902 | -22460 | -23001 |
| *... SG&A Margin* | *92.0%* | *75.3%* | *77.4%* | *79.6%* | *76.1%* | *68.7%* | *64.9%* | *63.2%* | *62.1%* | *61.0%* | *59.9%* | *59.8%* | *59.8%* | *59.7%* |
| Depreciation & Amortisation | 581 | 473 | 695 | 655 | 636 | 631 | 642 | 665 | 695 | 731 | 770 | 810 | 848 | 885 |
| **EBIT** | **-122** | **1685** | **1738** | **2206** | **3835** | **6749** | **9048** | **11135** | **13058** | **14058** | **15023** | **15334** | **15631** | **15919** |
| Add: Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **EBITA** | **-122** | **1685** | **1738** | **2206** | **3835** | **6749** | **9048** | **11135** | **13058** | **14058** | **15023** | **15334** | **15631** | **15919** |
| *... Margin* | *-1.3%* | *13.4%* | *11.4%* | *11.8%* | *17.8%* | *27.1%* | *32.4%* | *36.6%* | *40.1%* | *41.1%* | *42.2%* | *41.9%* | *41.6%* | *41.3%* |
| *... Growth* | | | | | | | | | | | | | | |
| Add: Depreciation | 581 | 473 | 695 | 655 | 636 | 631 | 642 | 665 | 695 | 731 | 770 | 810 | 848 | 885 |
| **EBITDA** | **458** | **2,159** | **2,433** | **2,861** | **4,472** | **7,380** | **9,690** | **11,799** | **13,753** | **14,790** | **15,793** | **16,143** | **16,479** | **16,805** |
| *... Margin* | *4.9%* | *17.2%* | *16.0%* | *15.3%* | *20.8%* | *29.6%* | *34.7%* | *38.8%* | *42.2%* | *43.2%* | *44.4%* | *44.1%* | *43.9%* | *43.6%* |
| Less: Tax | 116 | -16 | -243 | -251 | -321 | -565 | -1,002 | -1,347 | -1,660 | -1,949 | -2,099 | -2,243 | -2,290 | -2,335 |
| Less: Minority Interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Less: Increase of Working Capital | 3,047 | -1,181 | -590 | 1,181 | 1,181 | 2,362 | 2,362 | 2,362 | 2,362 | 2,362 | 2,362 | 2,362 | 2,362 | 2,362 |
| Less: Capex | -283 | -377 | -456 | -561 | -645 | -748 | -839 | -911 | -978 | -1,026 | -1,068 | -1,098 | -1,127 | -1,155 |
| *... Capex:Depreciation* | *0.5x* | *0.8x* | *0.7x* | *0.9x* | *1.0x* | *1.2x* | *1.3x* | *1.4x* | *1.4x* | *1.4x* | *1.4x* | *1.4x* | *1.3x* | *1.3x* |
| Less: Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **Free Cash Flow** | **3,339** | **584** | **1,144** | **3,230** | **4,687** | **8,429** | **10,211** | **11,903** | **13,477** | **14,177** | **14,988** | **15,164** | **15,424** | **15,677** |
| *... FCF Growth* | *-285.6%* | *-82.5%* | *95.8%* | *182.3%* | *45.1%* | *79.8%* | *21.1%* | *16.6%* | *13.2%* | *5.2%* | *5.7%* | *1.2%* | *1.7%* | *1.6%* |
| **PV of FCF** | **3,339** | **566** | **1,010** | **2,596** | **3,431** | **5,620** | **6,201** | **6,583** | **6,789** | **6,504** | **6,263** | **5,771** | **5,347** | **4,950** |
| Bull Case | | | | | | | | | | | | | | |

| **WACC** | | | **DCF Valuation** | |
|---|---|---|---|---|
| Risk Free Rate | 3.0% | | Sum of PV of FCF | 61,065 |
| Market Risk Premium | 9.5% | | PV of Terminal Value | 81,378 |
| Equity Beta | 0.88 | | Enterprise Value | 142,443 |
| Cost of Equity | 11.4% | | Add: Net Cash FY24 | 7,508 |
| Cost of Debt (Pre-tax) | 6.0% | | Equity Value (RMB mn) | 149,951 |
| Cost of Debt (After tax) | 5.1% | | | |
| Target Debt weight | 25.0% | | Equity Value (USD mn) | $ 19,348 |
| Target Equity weight | 75.0% | | Equity Value (HKD mn) | 164,946 |
| Tax Rate | 15.0% | | FX | 1.10 |
| | | | Diluted weighted shares outstanding | 1,560 |
| **WACC** | **9.8%** | **Terminal Growth** 3.5% | **Value per Share, HKD** | **HK$ 105.8** |

资料来源：公司财报；HTI

**表 2.**

| Key financials | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| Revenue (Rmbm) | 9422 | 12581 | 15186 | 18691 |
| Operating Profit /Loss (RMBm) | -756 | 1,052 | 1,105 | 1,572 |
| Pre-tax profit / Loss (RMBm) | -190 | 1,618 | 1,671 | 2,138 |
| Net income to ord equity (RMBm) | (206) | 1,375 | 1,420 | 1,817 |
| Revenue growth | 52% | 34% | 21% | 23% |
| Net profit growth | n.a. | n.a. | 3.3% | 28.0% |
| Adjusted net income to ord equity (Rmbm) | (206) | 1,375 | 1,420 | 1,817 |
| ROE | -1.6% | 9.5% | 8.9% | 10.3% |

| Balance Sheet (Rmb'm) | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| Total cash and equivalents | 7,508 | 7,988 | 9,246 | 12,528 |
| Inventories | 822.2 | 623.8 | 69.9 | 67.5 |
| Account and other receivables | 376 | 1,883 | 3,103 | 961 |
| Trade receivables | 1,184 | 2,039 | 2,461 | 3,029 |
| Other current assets | 383 | 383 | 383 | 383 |
| **Total current assets** | **10,273** | **12,916** | **15,263** | **16,968** |
| Property, plant and equipment | 5,280 | 5,184 | 4,945 | 4,851 |
| Other non-current assets | 6,050 | 6,050 | 6,050 | 6,050 |
| **Total non-current assets** | **11,330** | **11,234** | **10,995** | **10,901** |
| **Total assets** | **21,603** | **24,150** | **26,258** | **27,869** |
| Contract liabilities | 256 | 256 | 256 | 256 |
| Trade and other payable | 358 | 673 | 762 | 735 |
| Bank borrowing | 405 | 405 | 405 | 405 |
| Other current liabilities | 3,350 | 4,497 | 5,095 | 4,916 |
| **Total current liabilities** | **4,369** | **5,831** | **6,519** | **6,313** |
| Bank borrowing | 2,412 | 2,412 | 2,412 | 2,412 |
| Contract liabilities | 568 | 568 | 568 | 568 |
| Other liabilities | 1,136 | 846 | 846 | 846 |
| **Total non-current liabilities** | **4,116** | **3,826** | **3,826** | **3,826** |
| **Total liabilities** | **8,485** | **9,657** | **10,345** | **10,139** |
| **Shareholder's equity** | **13,118** | **14,493** | **15,913** | **17,730** |
| Minority interests | - | - | - | - |
| **Total equity** | 13,118 | 14,493 | 15,913 | 17,730 |
| **Total liabilities & shareholders' equity** | **21,603** | **24,150** | **26,258** | **27,869** |

| Cash flow (Rmb'm) | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| **Operating profit** | **(756)** | **1,052** | **1,105** | **1,572** |
| Deprecation and amortisation | 581 | 473 | 695 | 655 |
| Changes in working capital | (3,047) | 1,181 | 590 | (1,181) |
| Other operating cash flow | 6,901 | (1,782) | (609) | 2,864 |
| **Cash generated from operations** | **3,679** | **925** | **1,781** | **3,910** |
| Capex | (283) | (377) | (456) | (561) |
| Other investing cash flow | - | - | - | - |
| **Net cash flow from investing activities** | **(283)** | **(377)** | **(456)** | **(561)** |
| Change in borrowings | (704) | - | - | - |
| Proceeds from changes in capital | - | - | - | - |
| Other financing cash flow | (68) | (68) | (68) | (68) |
| **Net cash flow from financing activities** | **(772)** | **(68)** | **(68)** | **(68)** |
| Cash at beginning of period | 7,508 | 7,988 | 9,246 | 12,528 |
| **Net change in cash** | **2,624** | **480** | **1,258** | **3,282** |
| Forex effects | - | - | - | - |
| **Implied cash at end of period** | 7,988 | 9,246 | 12,528 | 17,093 |
| **Free cash flow** | **3,396** | **547** | **1,326** | **3,350** |

| Profit & Loss (Rmb'm) | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| Total turnover | 9,422 | 12,581 | 15,186 | 18,691 |
| Cost of sales | 1,510 | 2,052 | 2,325 | 2,243 |
| **Gross profit** | 7,912 | 10,529 | 12,861 | 16,448 |
| Total operating costs | 8,668 | 9,477 | 11,756 | 14,876 |
| **Operating profit** | (756) | 1,052 | 1,105 | 1,572 |
| Operating EBITDA | 648 | 2,348 | 2,622 | 3,050 |
| **Depreciation and amortisation** | 581 | 473 | 695 | 655 |
| **Operating EBIT** | (122) | 1,685 | 1,738 | 2,206 |
| Interest income (expense) | 190 | 190 | 190 | 190 |
| Share of loss from an associate/JV | - | - | - | - |
| **Pre-tax profit** | (190) | 1,618 | 1,671 | 2,138 |
| Taxation | 16 | 243 | 251 | 321 |
| **Net Income** | (206) | 1,375 | 1,420 | 1,817 |
| Minorities | - | - | - | - |
| **Net Income to ord equity** | (206) | 1,375 | 1,420 | 1,817 |
| One-off expense | - | - | - | - |
| **Normalized net income** | **(206)** | **1,375** | **1,420** | **1,817** |

| Per Share Data | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| EPS (Rmb) | (0.13) | 0.84 | 0.87 | 1.12 |
| Revenue per share (Rmb) | 5.79 | 7.73 | 9.33 | 11.48 |
| Operating EBITDA per share (Rmb) | 0.28 | 1.33 | 1.49 | 1.76 |
| BVPS (Rmb) | 8.06 | 8.91 | 9.78 | 10.89 |
| DPS (Rmb) | - | - | - | - |
| Recurrent cash flow per share (Rmb) | 1.61 | 0.29 | 0.77 | 2.02 |
| Shares in issue (million) | 1,627 | 1,627 | 1,627 | 1,627 |
| Year end adjusted shares in issue (million) | 1,627 | 1,627 | 1,627 | 1,627 |

x

| Key Ratios | Dec-24A | Dec-25E | Dec-26E | Dec-27E |
|---|---|---|---|---|
| **Growth** | | | | |
| Revenue growth | 51.8% | 33.5% | 20.7% | 23.1% |
| Operating profit growth | 56.1% | 33.1% | 22.1% | 27.9% |
| Net profit growth | -80.0% | -767.5% | 3.3% | 28.0% |
| **Margins** | | | | |
| Gross margin | 84.0% | 83.7% | 84.7% | 88.0% |
| Operating EBITDA margin | 4.9% | 17.2% | 16.0% | 15.3% |
| Operating margin | -8.0% | 8.4% | 7.3% | 8.4% |
| Pretax profit margin | -2.0% | 12.9% | 11.0% | 11.4% |
| Tax rate | 0.0% | 15.0% | 15.0% | 15.0% |
| Net profit margin | -2.2% | 10.9% | 9.4% | 9.7% |
| **Key Ratios** | | | | |
| ROE | -1.6% | 9.5% | 8.9% | 10.3% |
| ROA | -1.0% | 5.7% | 5.4% | 6.5% |
| Capex/revenue | -3.0% | -3.0% | -3.0% | -3.0% |
| Current ratio (x) | 2.4 | 2.2 | 2.3 | 2.7 |
| Creditor days | 120 | 120 | 120 | 120 |
| Debtor days | 59 | 59 | 59 | 59 |
| Inventory days | 111 | 11 | 11 | 11 |
| Sales/avg assets | 0.8 | 1.1 | 1.1 | 1.2 |
| **Credit analysis** | | | | |
| Debt/EBITDA (x) | 7.7 | 1.5 | 1.3 | 1.1 |
| Debt/equity | 28% | 25% | 23% | 21% |
| Net debt to equity | -16% | -10% | -12% | -31% |

资料来源：公司财报；HTI

**APPENDIX 1**

**Summary**

The company announced its 1H25 results: revenue reached RMB 5.95 billion (+50.6% YoY), with total product sales exceeding RMB 5.23 billion (+37.3% YoY). 2Q25 product sales were over RMB 2.7 billion (+30% YoY, +13% QoQ). Gross profit was RMB 5.12 billion (+56.3% YoY), with a gross margin of 86.0% (+3.1ppts). R&D expenses were RMB 1.0 billion (-28.0% YoY), representing 16.9% of revenue (-18.5ppts). Selling expenses amounted to RMB 2.38 billion (+26.4% YoY), accounting for 45.4% of product revenue (-3.9ppts). Net profit for the period was RMB 830 million (vs. -RMB 390 million in 1H24). The company's cash reserves exceeded USD 2.0 billion.

**Comments**

The company is steadily advancing its five-year strategic plan, while its internationalization strategy is gaining momentum. Domestic commercialization performance continued to improve, with product growth mainly driven by: (1) the solid foundation of the oncology portfolio, including brand and combination advantages of PD-1 and other products, as well as revenue contribution from new launches such as KRAS G12C inhibitors and third-generation EGFR-TKIs; (2) the CVM pipeline, where new products such as PCSK9 and IGF-1R achieved smooth market access and rapid uptake. In addition, masitutide was successfully approved. On the profitability side, the company reported net profit of RMB 830 million, exceeding market expectations. This was primarily due to the recognition of the USD 80 million upfront payment from Roche for the DLL3 ADC licensing deal and improved R&D efficiency. Given the global MRCT of IBI363 (PD-1/IL-2α-bias), Phase III clinical studies of masitutide, IBI112 (IL-23p19), and IBI128 (XOI), as well as the enrollment progress of early-stage assets, we expect R&D spending in 2H25 to be higher than in 1H25, with full-year R&D expenses remaining in the RMB 2.1–2.8 billion range.

Founder Dr. Dechao Yu reiterated that the company is steadily progressing along its established pathway: targeting EBITDA breakeven by 2025, domestic revenue of RMB 20 billion by 2027, and at least five assets entering global multi-regional Phase III clinical trials by 2030. These clear strategic milestones demonstrate the company's determination to become a world-class biopharmaceutical enterprise and provide strong confidence to the market. The company also emphasized its internationalization strategy, actively recruiting global talent in clinical development, operations, and supply chain to lay a solid foundation for overseas clinical advancement of assets such as IBI363.

**Oncology: IBI363 is poised to become the next-generation backbone IO therapy, while the company's new ADC portfolio is driving an "IO + ADC" therapeutic upgrade.**

**IBI363 is being developed across the continuum from late-line to front-line and perioperative settings, targeting IO-pretreated and "cold tumor" populations.** A pivotal study in treatment-naïve melanoma (mucosal/acral subtypes) is ongoing. In lung cancer, the company has initiated a global multi-regional Phase III trial (MRCT) in IO-refractory sqNSCLC, enrolling ~600 patients across China, Japan, the US, Canada, the EU, and the UK. The study evaluates IBI363 (3 mg/kg monotherapy) versus docetaxel in unresectable, locally advanced nqNSCLC patients who progressed after platinum chemotherapy and PD-1/PD-L1 treatment, with OS as the primary endpoint. Preparations are underway for a Phase III trial in 3L MSS CRC, while Phase I/IIb trials in first-line NSCLC and CRC are planned, with readouts expected from 2026 onward. Additional indications under exploration include platinum-resistant ovarian cancer, EGFR-mutant NSCLC, and neoadjuvant therapy in nsqNSCLC.

Next-generation modalities are also advancing, including bispecific/dual-payload ADCs and trispecific TCEs. IBI3001 (EGFR/B7H3 ADC) is in global dose-escalation studies (China/US/Australia) and will move into combination regimens once the RP2D is defined. IBI3020 (CEACAM5 dual-payload ADC), leveraging a proprietary cytotoxin and optimized linker technology, is designed to overcome resistance and widen the therapeutic window. Global Phase I dose-escalation is ongoing at higher dose levels, with proof-of-concept (POC) data expected in 2025. Meanwhile, IBI3003 (GPRC5D/BCMA/CD3 trispecific TCE) is advancing in China and Australia with US enrollment starting soon. Early clinical signals are encouraging, with ORR and CR rates in multiple myeloma potentially comparable to CAR-T therapies, while addressing resistance seen in GPRC5D- or BCMA-targeted monotherapies.

**Cardiovascular & Metabolic (CVM): Masitidutide is expected to become a leading domestic brand in weight loss, diabetes, and liver protection, with accelerated ramp-up in sales supported by robust channel expansion.** The T2D indication is anticipated to receive approval in 2H25, while a Phase III trial in adolescent obesity is about to begin. Market feedback has been positive, with pricing set ~30% below competitors and synergistic online/offline channel strategies expected to drive rapid uptake.

The company is also advancing differentiated oral GLP-1 programs. IBI3032, though based on an orforglipron backbone, demonstrates a longer half-life and 5–10x higher oral exposure than peer molecules, while carrying lower patent risk. Beyond diabetes and obesity, IBI3032 has potential in hypertension, complementing other CVM pipeline assets such as the xanthine oxidase inhibitor (XOI), reinforcing its potential as a next-generation cornerstone product.

**The company has a rich pipeline of R&D catalysts in 2025. Key programs to watch include:**

1) IBI363: Initiation of a Phase III trial in 3L MSS CRC; Phase I/IIb readouts expected in 1L NSCLC and 1L CRC (2026).
2) IBI343 (CLDN18.2 ADC): Global registrational MRCT in 2L pancreatic cancer expected to initiate (2H25–26); Phase I data readout in 1L pancreatic cancer.
3) IBI354 (HER2 ADC): Phase III readout in platinum-resistant ovarian cancer; potential initiation of Phase III in HER2+ breast cancer.
4) IBI3003 (GPRC5D/BCMA/CD3): Phase I data readout (2H25).
5) Masitidutide: T2D indication approval anticipated (2H25); topline results from the DREAMS-3 and GLORY-2 studies expected (2H25); Phase I readout in adolescent obesity and initiation of Phase III (2H25).
6) IBI128 (XOI): Phase II data presentation at the APLAR Annual Meeting (Sep 2025) and initiation of Phase III (2H25).
7) IBI3032 (oral GLP-1 small molecule): Entry into Phase I in China and the US (Q3 2025), with partial data expected in 2H25.
8) IBI3002 (TSLP/IL-4Rα): Preliminary data readout (2H25).
9) IBI356 (OX40L): Potential Phase I readout and initiation of Phase II (2H25).
10) IBI3016 (AGT siRNA): Phase I data presentation at the American Heart Association (AHA) Scientific Sessions (2H25).

**Earnings Forecast and Valuation Recommendation**

Based on the company's 2025 H1 revenue performance, we have raised our earnings forecasts and updated our valuation model. We now project total revenue of RMB 12.58/15.19/18.69 billion in 2025–27 (vs. previous estimates of RMB 11.86/14.34/18.17 billion), representing YoY growth of +34%/+21%/+23%. We expect the company to turn profitable in 2025, with net profit reaching RMB 1.38 billion (vs. previous estimate of RMB 380 million). Using a DCF model based on FY26–37 cash flows, and assuming WACC of 9.8% (unchanged), perpetual growth of 3.5% (unchanged), and an exchange rate of RMB:HKD = 1:1.14, we revise our target price to HKD 105.8 per share (vs. previous HKD 90.1), and maintain our "Outperform" rating.

**Risks:** risks in new drug research and development, risks in new drug approval, risks in commercializing new drugs.

**APPENDIX 2**

**ESG Comments**

**Environmental:**

the overall performance of company on environment is good

**Social:**

the overall performance of company on society is good

**Governance:**

the overall performance of company on government is good

## 附录 APPENDIX

### 重要信息披露

本研究报告由海通国际分销，海通国际是由海通国际研究有限公司(HTIRL)，Haitong Securities India Private Limited (HSIPL)，Haitong International Japan K.K. (HTIJKK)和海通国际证券有限公司(HTISCL)的证券研究团队所组成的全球品牌，海通国际证券集团(HTISG)各成员分别在其许可的司法管辖区内从事证券活动。

### IMPORTANT DISCLOSURES

This research report is distributed by Haitong International, a global brand name for the equity research teams of Haitong International Research Limited ("HTIRL"), Haitong Securities India Private Limited ("HSIPL"), Haitong International Japan K.K. ("HTIJKK"), Haitong International Securities Company Limited ("HTISCL"), and any other members within the Haitong International Securities Group of Companies ("HTISG"), each authorized to engage in securities activities in its respective jurisdiction.

**HTIRL 分析师认证 Analyst Certification**:

我， 孟科含，在此保证（i）本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点，并且（ii）我的报酬中没有任何部分与本研究报告中表达的具体建议或观点直接或间接相关；及就此报告中所讨论目标公司的证券，我们（包括我们的家属）在其中均不持有任何财务利益。我和我的家属（我已经告知他们）将不会在本研究报告发布后的 3 个工作日内交易此研究报告所讨论目标公司的证券。I, Kehan Meng, certify that (i) the views expressed in this research report accurately reflect my personal views about any or all of the subject companies or issuers referred to in this research and (ii) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report; and that I (including members of my household) have no financial interest in the security or securities of the subject companies discussed. I and my household, whom I have already notified of this, will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published.

我， 宁嘉骏，在此保证（i）本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点，并且（ii）我的报酬中没有任何部分与本研究报告中表达的具体建议或观点直接或间接相关；及就此报告中所讨论目标公司的证券，我们（包括我们的家属）在其中均不持有任何财务利益。我和我的家属（我已经告知他们）将不会在本研究报告发布后的 3 个工作日内交易此研究报告所讨论目标公司的证券。I, Jiajun Ning, certify that (i) the views expressed in this research report accurately reflect my personal views about any or all of the subject companies or issuers referred to in this research and (ii) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report; and that I (including members of my household) have no financial interest in the security or securities of the subject companies discussed. I and my household, whom I have already notified of this, will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published.

**利益冲突披露 Conflict of Interest Disclosures**

海通国际及其某些关联公司可从事投资银行业务和/或对本研究中的特定股票或公司进行做市或持有自营头寸。就本研究报告而言，以下是有关该等关系的披露事项（以下披露不能保证及时无遗漏，如需了解及时全面信息，请发邮件至 ERD-Disclosure@htisec.com）

HTI and some of its affiliates may engage in investment banking and / or serve as a market maker or hold proprietary trading positions of certain stocks or companies in this research report. As far as this research report is concerned, the following are the disclosure matters related to such relationship (As the following disclosure does not ensure timeliness and completeness, please send an email to ERD-Disclosure@htisec.com if timely and comprehensive information is needed).

No Disclosure

**评级定义（从 2020 年 7 月 1 日开始执行）：**

海通国际（以下简称"HTI"）采用相对评级系统来为投资者推荐我们覆盖的公司：优于大市、中性或弱于大市。投资者应仔细阅读 HTI 的评级定义。并且 HTI 发布分析师观点的完整信息，投资者应仔细阅读全文而非仅看评级。在任何情况下，分析师的评级和研究都不能作为投资建议。投资者的买卖股票的决策应基于各自情况（比如投资者的现有持仓）以及其他因素。

**分析师股票评级**

**优于大市**，未来 12-18 个月内预期相对基准指数涨幅在 10%以上，基准定义如下

**中性**，未来 12-18 个月内预期相对基准指数变化不大，基准定义如下。根据 FINRA/NYSE 的评级分布规则，我们会将中性评级划入持有这一类别。

**弱于大市**，未来 12-18 个月内预期相对基准指数跌幅在 10%以上，基准定义如下

各地股票基准指数：日本 – TOPIX, 韩国 – KOSPI, 台湾 – TAIEX, 印度 – Nifty100, 美国 – SP500; 其他所有中国概念股 – MSCI China.

**Ratings Definitions (from 1 Jul 2020):**

Haitong International uses a relative rating system using Outperform, Neutral, or Underperform for recommending the stocks we cover to investors. Investors should carefully read the definitions of all ratings used in Haitong International Research. In addition, since Haitong International Research contains more complete information concerning the analyst's views, investors should carefully read Haitong International Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

**Analyst Stock Ratings**

**Outperform:** The stock's total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark, as indicated below.

**Neutral:** The stock's total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark, as indicated below. For purposes only of FINRA/NYSE ratings distribution rules, our Neutral rating falls into a hold rating category.

**Underperform:** The stock's total return over the next 12-18 months is expected to be below the return of its relevant broad market benchmark, as indicated below.

**Benchmarks for each stock's listed region are as follows: Japan – TOPIX, Korea – KOSPI, Taiwan – TAIEX, India – Nifty100, US – SP500; for all other China-concept stocks – MSCI China.**

| | 截至 2025 年 6 月 30 日海通国际股票研究评级分布 | | | 截至 2025 年 3 月 31 日海通国际股票研究评级分布 | | |
|---|---|---|---|---|---|---|
| | 优于大市 | 中性 (持有) | 弱于大市 | 优于大市 | 中性 (持有) | 弱于大市 |
| 海通国际股票研究覆盖率 | 92.6% | 7.2% | 0.2% | 92.2% | 7.5% | 0.3% |
| 投资银行客户* | 2.9% | 4.1% | 0.0% | 3.3% | 3.5% | 0.0% |

*在每个评级类别里投资银行客户所占的百分比。

上述分布中的买入，中性和卖出分别对应我们当前优于大市，中性和落后大市评级。

只有根据 FINRA/NYSE 的评级分布规则，我们才将中性评级划入持有这一类别。请注意在上表中不包含非评级的股票。

**此前的评级系统定义（直至 2020 年 6 月 30 日）：**

买入，未来 12-18 个月内预期相对基准指数涨幅在 10%以上，基准定义如下

中性，未来 12-18 个月内预期相对基准指数变化不大，基准定义如下。根据 FINRA/NYSE 的评级分布规则，我们会将中性评级划入持有这一类别。

卖出，未来 12-18 个月内预期相对基准指数跌幅在 10%以上，基准定义如下

各地股票基准指数：日本 – TOPIX, 韩国 – KOSPI, 台湾 – TAIEX, 印度 – Nifty100; 其他所有中国概念股 – MSCI China.

| | Haitong International Equity Research Ratings Distribution, as of June 30, 2025 | | | Haitong International Equity Research Ratings Distribution, as of March 31, 2025 | | |
|---|---|---|---|---|---|---|
| | Outperform | Neutral (hold) | Underperform | Outperform | Neutral (hold) | Underperform |
| HTI Equity Research Coverage | 92.6% | 7.2% | 0.2% | 92.2% | 7.5% | 0.3% |
| IB clients* | 2.9% | 4.1% | 0.0% | 3.3% | 3.5% | 0.0% |

*Percentage of investment banking clients in each rating category.

BUY, Neutral, and SELL in the above distribution correspond to our current ratings of Outperform, Neutral, and Underperform.

For purposes only of FINRA/NYSE ratings distribution rules, our Neutral rating falls into a hold rating category. Please note that stocks with an NR designation are not included in the table above.

**Previous rating system definitions (until 30 Jun 2020):**

**BUY:** The stock's total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark, as indicated below.

**NEUTRAL:** The stock's total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark, as indicated below. For purposes only of FINRA/NYSE ratings distribution rules, our Neutral rating falls into a hold rating category.

**SELL:** The stock's total return over the next 12-18 months is expected to be below the return of its relevant broad market benchmark, as indicated below.

**Benchmarks for each stock's listed region are as follows: Japan – TOPIX, Korea – KOSPI, Taiwan – TAIEX, India – Nifty100; for all other China-concept stocks – MSCI China.**

**海通国际非评级研究：** 海通国际发布计量、筛选或短篇报告，并在报告中根据估值和其他指标对股票进行排名，或者基于可能的估值倍数提出建议价格。这种排名或建议价格并非为了进行股票评级、提出目标价格或进行基本面估值，而仅供参考使用。

**Haitong International Non-Rated Research:** Haitong International publishes quantitative, screening or short reports which may rank stocks according to valuation and other metrics or may suggest prices based on possible valuation multiples. Such rankings or suggested prices do not purport to be stock ratings or target prices or fundamental values and are for information only.

**海通国际 A 股覆盖：** 海通国际可能会就沪港通及深港通的中国 A 股进行覆盖及评级。国泰海通证券（601211.CH），海通国际于上海的母公司，也会于中国发布中国 A 股的研究报告。但是，海通国际使用与国泰海通证券不同的评级系统，所以海通国际与国泰海通证券的中国 A 股评级可能有所不同。

**Haitong International Coverage of A-Shares:** Haitong International may cover and rate A-Shares that are subject to the Hong Kong Stock Connect scheme with Shanghai and Shenzhen. GUOTAI HAITONG SECURITIES (601211 CH), the ultimate parent company of HTISG based in Shanghai, covers and publishes research on these same A-Shares for distribution in mainland China. However, the rating system employed by GTHS differs from that used by HTI and as a result there may be a difference in the HTI and GTHS ratings for the same A-share stocks.

**海通国际优质 100 A 股（Q100）指数：** 海通国际 Q100 指数是一个包括 100 支由国泰海通证券覆盖的优质中国 A 股的计量产品。这些股票是通过基于质量的筛选过程，并结合对国泰海通证券 A 股团队自下而上的研究。海通国际每季对 Q100 指数成分作出复审。

**Haitong International Quality 100 A-share (Q100) Index:** HTI's Q100 Index is a quant product that consists of 100 of the highest-quality A-shares under coverage at GTHS in Shanghai. These stocks are carefully selected through a quality-based screening process in combination with a review of the GTHS A-share team's bottom-up research. The Q100 constituent companies are reviewed quarterly.

**盟浪义利（FIN-ESG）数据通免责声明条款：** 在使用盟浪义利（FIN-ESG）数据之前，请务必仔细阅读本条款并同意本声明：

第一条 义利（FIN-ESG）数据系由盟浪可持续数字科技有限责任公司（以下简称"本公司"）基于合法取得的公开信息评估而成，本公司对信息的准确性及完整性不作任何保证。对公司的评估结果仅供参考，并不构成对任何个人或机构投资建议，也不能作为任何个人或机构购买、出售或持有相关金融产品的依据。本公司不对任何个人或机构投资者因使用本数据表述的评估结果造成的任何直接或间接损失负责。

第二条 盟浪并不因收到此评估数据而将收件人视为客户，收件人使用此数据时应根据自身实际情况作出自我独立判断。本数据所载内容反映的是盟浪在最初发布本数据日期当日的判断，盟浪有权在不发出通知的情况下更新、修订与发出其他与本数据所载内容不一致或有不同结论的数据。除非另行说明，本数据（如财务业绩数据等）仅代表过往表现，过往的业绩表现不作为日后回报的预测。

第三条

改、复制、编译、汇编、再次编辑、改编、删减、缩写、节选、发行、出租、展览、表演、放映、广播、信息网络传播、摄制、增加图标及说明等，否则因此给盟浪或其他第三方造成损失的，由用户承担相应的赔偿责任，盟浪不承担责任。

第四条 如本免责声明未约定，而盟浪网站平台载明的其他协议内容（如《盟浪网站用户注册协议》《盟浪网用户服务（含认证）协议》《盟浪网隐私政策》等）有约定的，则按其他协议的约定执行；若本免责声明与其他协议约定存在冲突或不一致的，则以本免责声明约定为准。

**SusallWave FIN-ESG Data Service Disclaimer**: Please read these terms and conditions below carefully and confirm your agreement and acceptance with these terms before using SusallWave FIN-ESG Data Service.

1. FIN-ESG Data is produced by SusallWave Digital Technology Co., Ltd. (In short, SusallWave)'s assessment based on legal publicly accessible information. SusallWave shall not be responsible for any accuracy and completeness of the information. The assessment result is for reference only. It is not for any investment advice for any individual or institution and not for basis of purchasing, selling or holding any relative financial products. We will not be liable for any direct or indirect loss of any individual or institution as a result of using SusallWave FIN-ESG Data.

2. SusallWave do not consider recipients as customers for receiving these data. When using the data, recipients shall make your own independent judgment according to your practical individual status. The contents of the data reflect the judgment of us only on the release day. We have right to update and amend the data and release other data that contains inconsistent contents or different conclusions without notification. Unless expressly stated, the data (e.g., financial performance data) represents past performance only and the past performance cannot be viewed as the prediction of future return.

3. The copyright of this data belongs to SusallWave, and we reserve all rights in accordance with the law. Without the prior written permission of our company, none of individual or institution can use these data for any profitable purpose. Besides, none of individual or institution can take actions such as amendment, replication, translation, compilation, re-editing, adaption, deletion, abbreviation, excerpts, issuance, rent, exhibition, performance, projection, broadcast, information network transmission, shooting, adding icons and instructions. If any loss of SusallWave or any third-party is caused by those actions, users shall bear the corresponding compensation liability. SusallWave shall not be responsible for any loss.

4. If any term is not contained in this disclaimer but written in other agreements on our website (e.g. *User Registration Protocol of SusallWave Website, User Service (including authentication) Agreement of SusallWave Website, Privacy Policy of Susallwave Website*), it should be executed according to other agreements. If there is any difference between this disclaim and other agreements, this disclaimer shall be applied.

**重要免责声明:**

**非印度证券的研究报告:** 本报告由海通国际证券集团有限公司（"HTISGL"）的全资附属公司海通国际研究有限公司（"HTIRL"）发行，该公司是根据香港证券及期货条例（第 571 章）持有第 4 类受规管活动（就证券提供意见）的持牌法团。该研究报告在 HTISGL 的全资附属公司 Haitong International (Japan) K.K.（"HTIJKK"）的协助下发行，HTIJKK 是由日本关东财务局监管为投资顾问。

**印度证券的研究报告:** 本报告由从事证券交易、投资银行及证券分析及受 Securities and Exchange Board of India（"SEBI"）监管的 Haitong Securities India Private Limited（"HTSIPL"）所发行，包括制作及发布涵盖 BSE Limited（"BSE"）和 National Stock Exchange of India Limited（"NSE"）上市公司（统称为「印度交易所」）的研究报告。HTSIPL 于 2016 年 12 月 22 日被收购并成为海通国际证券集团有限公司（"HTISG"）的一部分。

所有研究报告均以海通国际为名作为全球品牌，经许可由海通国际证券股份有限公司及/或海通国际证券集团的其他成员在其司法管辖区发布。

本文件所载信息和观点已被编译或源自可靠来源，但 HTIRL、HTISCL 或任何其他属于海通国际证券集团有限公司（"HTISG"）的成员对其准确性、完整性和正确性不做任何明示或暗示的声明或保证。本文件中所有观点均截至本报告日期，如有更改，恕不另行通知。本文件仅供参考使用。文件中提及的任何公司或其股票的说明并非意图展示完整的内容，本文件并非/不应被解释为对证券买卖的明示或暗示地出价或征价。在某些司法管辖区，本文件中提及的证券可能无法进行买卖。如果投资产品以投资者本国货币以外的币种进行计价，则汇率变化可能会对投资产生不利影响。过去的表现并不一定代表将来的结果。某些特定交易，包括设计金融衍生工具的，有产生重大风险的可能性，因此并不适合所有的投资者。您还应认识到本文件中的建议并非为您量身定制。分析师并未考虑到您自身的财务情况，如您的财务状况和风险偏好。因此您必须自行分析并在适用的情况下咨询自己的法律、税收、会计、金融和其他方面的专业顾问，以期在投资之前评估该项建议是否适合于您。若由于使用本文件所载的材料而产生任何直接或间接的损失，HTISG 及其董事、雇员或代理人对此均不承担任何责任。

除对本文内容承担责任的分析师除外，HTISG 及我们的关联公司、高级管理人员、董事和雇员，均可不时作为主事人就本文件所述的任何证券或衍生品持有长仓或短仓以及进行买卖。HTISG 的销售员、交易员和其他专业人士均可向 HTISG 的相关客户和公司提供与本文件所述意见相反的口头或书面市场评论意见或交易策略。HTISG 可做出与本文件所述建议或意见不一致的投资决策。但 HTIRL 没有义务来确保本文件的收件人了解到该等交易决定、思路或建议。

请访问海通国际网站 www.equities.htisec.com，查阅更多有关海通国际为预防和避免利益冲突设立的组织和行政安排的内容信息。

**非美国分析师披露信息:** 本项研究首页上列明的海通国际分析师并未在 FINRA 进行注册或者取得相应的资格，并且不受美国 FINRA 有关与本项研究目标公司进行沟通、公开露面和自营证券交易的第 2241 条规则之限制。

**IMPORTANT DISCLAIMER**

**For research reports on non-Indian securities:** The research report is issued by Haitong International Research Limited ("HTIRL"), a wholly owned subsidiary of Haitong International Securities Group Limited ("HTISGL") and a licensed corporation to carry on Type 4 regulated activity (advising on securities) for the purpose of the Securities and Futures Ordinance (Cap. 571) of Hong Kong, with the assistance of Haitong International (Japan) K.K. ("HTIJKK"), a wholly owned subsidiary of HTISGL and which is regulated as an Investment Adviser by the Kanto Finance Bureau of Japan.

**For research reports on Indian securities:** The research report is issued by Haitong Securities India Private Limited ("HSIPL"), an Indian company and a Securities and Exchange Board of India ("SEBI") registered Stock Broker, Merchant Banker and Research Analyst that, inter alia, produces and distributes research reports covering listed entities on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (collectively referred to as "Indian Exchanges"). HSIPL was acquired and became part of the Haitong International Securities Group of Companies ("HTISG") on 22 December 2016.

All the research reports are globally branded under the name Haitong International and approved for distribution by Haitong International Securities Company Limited ("HTISCL") and/or any other members within HTISG in their respective jurisdictions.

The information and opinions contained in this research report have been compiled or arrived at from sources believed to be reliable and in good faith but no representation or warranty, express or implied, is made by HTIRL, HTISCL, HSIPL, HTIJKK or any other members within HTISG from which this research report may be received, as to their accuracy, completeness or correctness. All opinions expressed herein are as of the date of this research report and are subject to change without notice. This research report is for information purpose only. Descriptions of any companies or their securities mentioned herein are not intended to be complete and this research report is not, and should not be construed expressly or impliedly as, an offer to buy or sell securities. The securities referred to in this research report may not be eligible for purchase or sale in some jurisdictions. If an investment product is denominated in a currency other than an investor's home currency, a change in exchange rates may adversely affect the investment. Past performance is not necessarily indicative of future results. Certain transactions, including those involving derivatives, give rise to substantial risk and are not suitable for all investors. You should also bear in mind that recommendations in this research report are not tailor-made for you. The analyst has not taken into account your unique financial circumstances, such as your financial situation and risk appetite. You must, therefore, analyze and should, where applicable, consult your own legal, tax, accounting, financial and other professional advisers to evaluate whether the recommendations suits you before investment. Neither HTISG nor any of its directors, employees or agents accepts any liability whatsoever for any direct or consequential loss arising from any use of the materials contained in this research report.

HTISG and our affiliates, officers, directors, and employees, excluding the analysts responsible for the content of this document, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research report. Sales, traders, and other professionals of HTISG may provide oral or written market commentary or trading strategies to the relevant clients and the companies within HTISG that reflect opinions that are contrary to the opinions expressed in this research report. HTISG may make investment decisions that are inconsistent with the recommendations or views expressed in this research report. HTI is under no obligation to ensure that such other trading decisions, ideas or recommendations are brought to the attention of any recipient of this research report.

Please refer to HTI's website www.equities.htisec.com for further information on HTI's organizational and administrative arrangements set up for the prevention and avoidance of conflicts of interest with respect to Research.

**Non U.S. Analyst Disclosure:** The HTI analyst(s) listed on the cover of this Research is (are) not registered or qualified as a research analyst with FINRA and are not subject to U.S. FINRA Rule 2241 restrictions on communications with companies that are the subject of the Research; public appearances; and trading securities by a research analyst.

**分发和地区通知:**

除非下文另有规定，否则任何希望讨论本报告或者就本项研究中讨论的任何证券进行任何交易的收件人均应联系其所在国家或地区的海通国际销售人员。

**香港投资者的通知事项:** 海通国际证券股份有限公司("HTISCL")负责分发该研究报告，HTISCL 是在香港有权实施第 1 类受规管活动（从事证券交易）的持牌公司。该研究报告并不构成《证券及期货条例》（香港法例第 571 章）（以下简称"SFO"）所界定的要约邀请，证券要约或公众要约。本研究报告仅提供给 SFO 所界定的"专业投资者"。本研究报告未经过证券及期货事务监察委员会的审查。您不应仅根据本研究报告中所载的信息做出投资决定。本研究报告的收件人就研究报告中产生或与之相关的任何事宜请联系 HTISCL 销售人员。

**美国投资者的通知事项:** 本研究报告由 HTIRL，HSIPL 或 HTIJKK 编写。 HTIRL，HSIPL，HTIJKK 以及任何非 HTISG 美国联营公司，均未在美国注册，因此不受美国关于研究报告编制和研究分析人员独立性规定的约束。本研究报告提供给依照 1934 年"美国证券交易法"第 15a-6 条规定的豁免注册的「美国主要机构投资者」（"Major U.S. Institutional Investor"）和「机构投资者」（"U.S. Institutional Investors"）。在向美国机构投资者分发研究报告时，Haitong International Securities (USA) Inc.（"HTI USA"）将对报告的内容负责。任何收到本研究报告的美国投资者，希望根据本研究报告提供的信息进行任何证券或相关金融工具买卖的交易，只能通过 HTI USA。HTI USA 位于 1460 Broadway, Suite 11017, New York, NY 10036 USA，电话+1 212-351-6052。 HTI USA 是在美国于 U.S. Securities and Exchange Commission（"SEC"）注册的经纪商，也是 Financial Industry Regulatory Authority, Inc.（"FINRA"）的成员。 HTIUSA 不负责编写本研究报告，也不负责其中包含的分析。在任何情况下，收到本研究报告的任何美国投资者，不得直接与分析师直接联系，也不得通过 HSIPL，HTIRL 或 HTIJKK 直接进行买卖证券或相关金融工具的交易。本研究报告中出现的 HSIPL，HTIRL 或 HTIJKK 分析师没有注册或具备 FINRA 的研究分析师资格，因此可能不受 FINRA 第 2241 条规定的与目标公司的交流，公开露面和分析师账户持有的交易证券等限制。投资本研究报告中讨论的任何非美国证券或相关金融工具（包括 ADR）可能存在一定风险。非美国发行的证券可能没有注册，或不受美国法规的约束。有关非美国证券或相关金融工具的信息可能有限制。外国公司可能不受审计和汇报的标准以及与美国境内生效相符的监管要求。本研究报告中以美元以外的其他货币计价的任何证券或相关金融工具的投资或收益的价值受汇率波动的影响，可能对该等证券或相关金融工具的价值或收入产生正面或负面影响。美国收件人的所有问询请联系:

Haitong International Securities (USA) Inc.
1460 Broadway, Suite 11017
New York, NY 10036
联系人电话：+1 212-351-6052

**DISTRIBUTION AND REGIONAL NOTICES**

Except as otherwise indicated below, any Recipient wishing to discuss this research report or effect any transaction in any security discussed in HTI's research should contact the Haitong International salesperson in their own country or region.

**Notice to Hong Kong investors:** The research report is distributed by Haitong International Securities Company Limited ("HTISCL"), which is a licensed corporation to carry on Type 1 regulated activity (dealing in securities) in Hong Kong. This research report does not constitute a solicitation or an offer of securities or an invitation to the public within the meaning of the SFO. This research report is only to be circulated to "Professional Investors" as defined in the SFO. This research report has not been reviewed by the Securities and Futures Commission. You should not make investment decisions solely on the basis of the information contained in this research report. Recipients of this research report are to contact HTISCL salespersons in respect of any matters arising from, or in connection with, the research report.

**Notice to U.S. investors**: As described above, this research report was prepared by HTIRL, HSIPL or HTIJKK. Neither HTIRL, HSIPL, HTIJKK, nor any of the non U.S. HTISG affiliates is registered in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" and "U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended. When distributing research reports to "U.S. institutional investors," HTI USA will accept the responsibilities for the content of the reports. Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Haitong International Securities (USA)

Inc. ("HTI USA"), located at 1460 Broadway, Suite 11017, New York, NY 10036, USA; telephone +1 212-351-6052. HTI USA is a broker-dealer registered in the U.S. with the U.S. Securities and Exchange Commission (the "SEC") and a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"). HTI USA is not responsible for the preparation of this research report nor for the analysis contained therein. Under no circumstances should any U.S. recipient of this research report contact the analyst directly or effect any transaction to buy or sell securities or related financial instruments directly through HSIPL, HTIRL or HTIJKK. The HSIPL, HTIRL or HTIJKK analyst(s) whose name appears in this research report is not registered or qualified as a research analyst with FINRA and, therefore, may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to U.S. regulations. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the U.S. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments. All inquiries by U.S. recipients should be directed to:

Haitong International Securities (USA) Inc.
1460 Broadway, Suite 11017

New York, NY 10036

Attn: Sales Desk at +1 212-351-6052

**中华人民共和国的通知事项：**在中华人民共和国（下称"中国"，就本报告目的而言，不包括香港特别行政区、澳门特别行政区和台湾）只有根据适用的中国法律法规而收到该材料的人员方可使用该材料。并且根据相关法律法规，该材料中的信息并不构成"在中国从事生产、经营活动"。本文件在中国并不构成相关证券的公共发售或认购。无论根据法律规定或其他任何规定，在取得中国政府所有的批准或许可之前，任何法人或自然人均不得直接或间接地购买本材料中的任何证券或任何实益权益。接收本文件的人员须遵守上述限制性规定。

**加拿大投资者的通知事项：**在任何情况下该等材料均不得被解释为在任何加拿大的司法管辖区内出售证券的要约或认购证券的要约邀请。本材料中所述证券在加拿大的任何要约或出售行为均只能在豁免向有关加拿大证券监管机构提交招股说明书的前提下由 Haitong International Securities (USA) Inc.（"HTI USA"）予以实施，该公司是一家根据 National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations（"NI 31-103"）的规定得到「国际交易商豁免」（"International Dealer Exemption"）的交易商，位于艾伯塔省、不列颠哥伦比亚省、安大略省和魁北克省。在加拿大，该等材料在任何情况下均不得被解释为任何证券的招股说明书、发行备忘录、广告或公开发行。加拿大的任何证券委员会或类似的监管机构均未审查或以任何方式批准该等材料、其中所载的信息或所述证券的优点，任何与此相反的声明即属违法。在收到该等材料时，每个加拿大的收件人均将被视为属于 National Instrument 45-106 Prospectus Exemptions 第 1.1 节或者 Securities Act (Ontario)第 73.3(1)节所规定的「认可投资者」（"Accredited Investor"），或者在适用情况下 National Instrument 31-103 第 1.1 节所规定的「许可投资者」（"Permitted Investor"）。

**新加坡投资者的通知事项：**本研究报告由 Haitong International Securities (Singapore) Pte Ltd（"HTISSPL"）于新加坡提供。HTISSPL 是符合《财务顾问法》2001（"FAA"）定义的豁免财务顾问，可（a）提供关于证券，集体投资计划的部分，交易所衍生品合约和场外衍生品合约的建议（b）发行或公布有关证券、交易所衍生品合约和场外衍生品合约的研究分析或研究报告。本研究报告仅提供给符合《证券及期货法》2001 第 4A 条项下规定的机构投资者。对于因本研究报告而产生的或与之相关的任何问题，本研究报告的收件人应通过以下信息与 HTISSPL 联系：

Haitong International Securities (Singapore) Pte. Ltd

10 Collyer Quay, #19-01 - #19-05 Ocean Financial Centre, Singapore 049315

电话: (65) 6713 0473

**日本投资者的通知事项：**本研究报告由海通国际证券有限公司所发布，旨在分发给从事投资管理的金融服务提供商或注册金融机构（根据日本金融机构和交易法（"FIEL"））第 61（1）条，第 17-11（1）条的执行及相关条款）。

**英国及欧盟投资者的通知事项：**本报告由从事投资顾问的 Haitong International Securities Company Limited 所发布，本报告只面向有投资相关经验的专业客户发布。任何投资或与本报告相关的投资行为只面对此类专业客户。没有投资经验或相关投资经验的客户不得依赖本报告。Haitong International Securities Company Limited 的分支机构的净长期或短期金融权益可能超过本研究报告中提及的实体已发行股本总额的 0.5％。特别提醒有些英文报告有可能此前已经通过中文或其它语言完成发布。

**澳大利亚投资者的通知事项：**Haitong International Securities (Singapore) Pte Ltd, Haitong International Securities Company Limited 和 Haitong International Securities (UK) Limited 分别根据澳大利亚证券和投资委员会（以下简称"ASIC"）公司（废除及过度性）文书第 2016/396 号规章在澳大利亚分发本项研究，该等规章免除了根据 2001 年《公司法》在澳大利亚为批发客户提供金融服务时海通国际需持有澳大利亚金融服务许可的要求。ASIC 的规章副本可在以下网站获取：www.legislation.gov.au。海通国际提供的金融服务受外国法律法规规定的管制，该等法律与在澳大利亚所适用的法律存在差异。

**印度投资者的通知事项：**本报告由从事证券交易、投资银行及证券分析及受 Securities and Exchange Board of India（"SEBI"）监管的 Haitong Securities India Private Limited（"HTSIPL"）所发布，包括制作及发布涵盖 BSE Limited（"BSE"）和 National Stock Exchange of India Limited（"NSE"）（统称为「印度交易所」）研究报告。

（条款链接：https://www.htisec.com/sites/all/themes/hitong/files/india/Terms%20and%20Conditions%20for%20Research%20Analyst.pdf）

研究机构名称: Haitong Securities India Private Limited

SEBI 研究分析师注册号: INH000002590

地址: 1203A, Floor 12A, Tower 2A, One World Center

841 Senapati Bapat Marg, Elphinstone Road, Mumbai 400 013, India

CIN U74140MH2011FTC224070

电话: +91 22 43156800 传真:+91 22 24216327

合规和申诉办公室联系人： Prasanna Chandwaskar； 电话: +91 22 43156803; 电子邮箱: prasanna.chandwaskar@htisec.com

“请注意，SEBI 授予的注册和 NISM 的认证并不保证中介的表现或为投资者提供任何回报保证”。



**People’s Republic of China (PRC):** In the PRC, the research report is directed for the sole use of those who receive the research report in accordance with the applicable PRC laws and regulations. Further, the information on the research report does not constitute "production and business activities in the PRC" under relevant PRC laws. This research report does not constitute a public offer of the security, whether by sale or subscription, in the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the security or any beneficial interest therein without obtaining all prior PRC government approvals or licenses that are required, whether statutorily or otherwise. Persons who come into possession of this research are required to observe these restrictions.

**Notice to Canadian Investors**: Under no circumstances is this research report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by Haitong International Securities (USA) Inc., a dealer relying on the “international dealer exemption” under National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations (“NI 31-103”) in Alberta, British Columbia, Ontario and Quebec. This research report is not, and under no circumstances should be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of any securities in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this research report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Upon receipt of this research report, each Canadian recipient will be deemed to have represented that the investor is an “accredited investor” as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions or, in Ontario, in section 73.3(1) of the Securities Act (Ontario), as applicable, and a “permitted client” as such term is defined in section 1.1 of NI 31-103, respectively.

**Notice to Singapore investors:** This research report is provided in Singapore by or through Haitong International Securities (Singapore) Pte Ltd (“HTISSPL”). HTISSPL is an Exempt Financial Adviser under the Financial Advisers Act 2001 (“FAA”) to (a) advise on securities, units in a collective investment scheme, exchange-traded derivatives contracts and over-the-counter derivatives contracts and (b) issue or promulgate research analyses or research reports on securities, exchange-traded derivatives contracts and over-the-counter derivatives contracts. This research report is only provided to institutional investors, within the meaning of Section 4A of the Securities and Futures Act 2001. Recipients of this research report are to contact HTISSPL via the details below in respect of any matters arising from, or in connection with, the research report:

Haitong International Securities (Singapore) Pte. Ltd.

10 Collyer Quay, #19-01 - #19-05 Ocean Financial Centre, Singapore 049315

Telephone: (65) 6713 0473

**Notice to Japanese investors:** This research report is distributed by Haitong International Securities Company Limited and intended to be distributed to Financial Services Providers or Registered Financial Institutions engaged in investment management (as defined in the Japan Financial Instruments and Exchange Act ("FIEL") Art. 61(1), Order for Enforcement of FIEL Art. 17-11(1), and related articles).

**Notice to UK and European Union investors:** This research report is distributed by Haitong International Securities Company Limited. This research is directed at persons having professional experience in matters relating to investments. Any investment or investment activity to which this research relates is available only to such persons or will be engaged in only with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this research. Haitong International Securities Company Limited’s affiliates may have a net long or short financial interest in excess of 0.5% of the total issued share capital of the entities mentioned in this research report. Please be aware that any report in English may have been published previously in Chinese or another language.

**Notice to Australian investors:** The research report is distributed in Australia by Haitong International Securities (Singapore) Pte Ltd, Haitong International Securities Company Limited, and Haitong International Securities (UK) Limited in reliance on ASIC Corporations (Repeal and Transitional) Instrument 2016/396, which exempts those HTISG entities from the requirement to hold an Australian financial services license under the Corporations Act 2001 in respect of the financial services it provides to wholesale clients in Australia. A copy of the ASIC Class Orders may be obtained at the following website, www.legislation.gov.au. Financial services provided by Haitong International Securities (Singapore) Pte Ltd, Haitong International Securities Company Limited, and Haitong International Securities (UK) Limited are regulated under foreign laws and regulatory requirements, which are different from the laws applying in Australia.

**Notice to Indian investors:** The research report is distributed by Haitong Securities India Private Limited (“HSIPL”), an Indian company and a Securities and Exchange Board of India (“SEBI”) registered Stock Broker, Merchant Banker and Research Analyst that, inter alia, produces and distributes research reports covering listed entities on the BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) (collectively referred to as “Indian Exchanges”).

(Link to the Terms and Conditions document: https://www.htisec.com/sites/all/themes/hitong/files/india/Terms%20and%20Conditions%20for%20Research%20Analyst.pdf)

Name of the entity: Haitong Securities India Private Limited

SEBI Research Analyst Registration Number: INH000002590

Address : 1203A, Floor 12A, Tower 2A, One World Center

841 Senapati Bapat Marg, Elphinstone Road, Mumbai 400 013, India

CIN U74140MH2011FTC224070

Ph: +91 22 43156800 Fax:+91 22 24216327

Details of the Compliance Officer and Grievance Officer : Prasanna Chandwaskar : Ph: +91 22 43156803; Email id: prasanna.chandwaskar@htisec.com

“Please note that Registration granted by SEBI and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.

**Recommendation Chart**




1. 10 Apr 2023 OUTPERFORM at 38.35 target 50.60.
2. 12 May 2023 OUTPERFORM at 39.75 target 50.60.
3. 25 Aug 2023 OUTPERFORM at 34.65 target 51.60.
4. 25 Mar 2024 OUTPERFORM at 36.00 target 59.90.
5. 27 May 2024 OUTPERFORM at 35.90 target 59.90.
6. 2 Sep 2024 OUTPERFORM at 42.45 target 67.80.
7. 3 Mar 2025 OUTPERFORM at 43.20 target 60.20.
8. 1 Apr 2025 OUTPERFORM at 46.60 target 61.40.
9. 6 May 2025 OUTPERFORM at 54.30 target 62.50.
10. 9 Jun 2025 OUTPERFORM at 73.15 target 90.10.
11. 1 Jul 2025 OUTPERFORM at 78.40 target 90.10.

Source: Company data Bloomberg, HTI estimates